Riskpilot← Back to searchSign inGet full accessGram Medicin AB
ABActiveOrg 5567853154Torstenssonsgatan 15General medical practice activities · NACE 8621Est. 20090 employees
Revenue 2024
SEK 6,1M
-24% vs 2023
EBITDA margin
75.9%
-34% vs 2023
Equity ratio
58.6%
Financial strength
Net profit 2024
SEK 8,2M
-18% vs 2023
| Revenue | SEK 6,1M | -24% |
| EBITDA | SEK 4,6M | -34% |
| Net profit | SEK 8,2M | -18% |
| Total assets | SEK 77,5M | +51% |
| Equity | SEK 45,4M | +22% |
| Employees | 0 | — |
Legal name
Gram Medicin AB
Org number
5567853154
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
6 juli 2009
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva konsultverksamhet inom sjukvård, hälsovård, friskvård samt journalistik inom nämnda områden. Samt äga och förvalta såväl fast som lös egendom, aktier och andra värdepapper samt därmed förenlig verksamhet.
Address
Torstenssonsgatan 15
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 5 699 | 7 414 | 9 754 | 7 921 | 6 055 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 5 061 | 6 505 | 8 202 | 6 952 | 4 595 |
| Depreciation & amort. | −6 | −6 | −6 | −6 | −5 |
| EBIT | 5 055 | 6 499 | 8 196 | 6 946 | 4 590 |
| Net financials | 59 | 377 | 1 010 | 5 350 | 5 343 |
| Profit before tax | 4 267 | 5 624 | 7 300 | 11 333 | 9 453 |
| Tax | −879 | −1 176 | −1 533 | −1 284 | −1 206 |
| Net profit | 3 388 | 4 448 | 5 767 | 10 049 | 8 247 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 27 352 | 32 223 | 40 502 | 51 486 | 77 514 |
| Equity | 17 708 | 21 972 | 27 552 | 37 405 | 45 448 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 914 | 2 269 | 2 841 | 3 008 | 20 513 |
| Total debt | 2 914 | 2 269 | 2 841 | 3 008 | 20 513 |
EBITDA margin
75.9%
This company
15.8%
Market median
+380% vs market
20202024
Equity ratio
58.6%
This company
38.2%
Market median
+53% vs market
20202024
Return on equity
18.1%
This company
18.4%
Market median
+2% vs market
20202024
Net profit margin
136.2%
This company
8.1%
Market median
+1581% vs market
20202024
Asset turnover
0.08×
This company
1.12×
Market median
-93% vs market
20202024
Debt / equity
0.71×
This company
0.62×
Market median
+15% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SM | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Gram Medicin AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sven Michael Christensson | Audit | 0 companies |
| Snickar Karl Johan Tobieson | Deputy Board Member | 0 companies |
| Anders Erik Hansen | Board of Directors | 0 companies |